Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.
Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter P
| Generic Name | Trade Name | Condition | Study Code | Study Name | Access to study | Access to results |
|---|---|---|---|---|---|---|
| PAN PI3K INHIBITOR | Not marketed | Endometrial Neoplasms | ARD11436 | NA | EudraCT: 2009-016707-30 | |
| PAN PI3K INHIBITOR | Not marketed | Breast Neoplasms | ARD11437 | NA | NCT01082068 | |
| PAN PI3K INHIBITOR | Not marketed | Breast Neoplasms | ARD11439 | NA | EudraCT: 2009-016862-10 | |
| PAN PI3K INHIBITOR | Not marketed | Solid Tumors | TCD11742 | NA | NCT01357330 | |
| PAN PI3K INHIBITOR | Not marketed | Neoplasms | TED12863 | NA | NCT01943838 | |
| PAN PI3K INHIBITOR | Not marketed | Solid Tumors | TED11883 | NA | NCT01392924 | |
| PAN PI3K AND MTOR INHIBITOR | Not marketed | Lymphoma or Leukemia | ARD12130 | NA | EudraCT: 2011-001616-57 | |
| PAN PI3K AND MTOR INHIBITOR | Not marketed | Indolent Lymphoma | TCD12012 | NA | NCT01410513 | |
| PAN PI3K AND MTOR INHIBITOR | Not marketed | Glioblastoma | TED11605 | NA | NCT01240460 | |
| PAN PI3K AND MTOR INHIBITOR | Not marketed | Neoplasms | TED12471 | NA | NCT01596270 | |
| PARACETAMOL | Doliprane | Pain | PARAC_L_00859 | NA | NCT00434681 | |
| PHOSPHATIDYL CHOLINE | Essentiale | Liver Disease | CHOLIL06301 | EPLID | NCT02517385 | |
| PI3K-B INHIBITOR | Not marketed | Solid Tumors, Lymphoma | TCD12739 | NA | NCT01673737 | |
| PLERIXAFOR | Mozobil | Non-Hodgkin's Lymphoma | ACT12781 | NA | NCT02221492 | |
| PLERIXAFOR | Mozobil | Multiple Myeloma | ACT13710 | NA | NCT02221479 | |
| PLERIXAFOR | Not marketed | Renal Impairment | AMD31001101 | NA | NCT00445302 | |
| PLERIXAFOR | Mozobil | Multiple Myeloma or Non-Hodgkin's Lyjmphoma | AMD3100-2104 | NA | NCT00322387 | |
| PLERIXAFOR | Mozobil | Multiple Myeloma or Non-Hodgkin's Lyjmphoma | AMD3100-2105 | NA | NCT00322491 | |
| PLERIXAFOR | Not marketed | Hodgkin's Disease | AMD3100-2106 | NA | NCT00396201 | |
| PLERIXAFOR | Mozobil | Multiple Myeloma | AMD3100-2108 | NA | NCT00396383 | |
| PLERIXAFOR | Mozobil | Multiple Myeloma or Non-Hodgkin's Lyjmphoma | AMD3100-2109 | NA | NCT00395967 | |
| PLERIXAFOR | Not marketed | Transplantation | AMD31002112 | NA | NCT00396331 | |
| PLERIXAFOR | Mozobil | Non-Hodgkin's Lymphoma or Hodgkin's Disease | AMD31002113 | NA | NCT00444912 | |
| PLERIXAFOR | Mozobil | Non-Hodgkin's Lymphoma | AMD31003101 | NA | NCT00103610 | |
| PLERIXAFOR | Mozobil | Multiple Myeloma | AMD31003102 | NA | NCT00103662 | |
| PLERIXAFOR | Mozobil | Multiple Myeloma or Non-Hodgkin's Lyjmphoma | AMD3100C201 | NA | NCT00396266 | |
| PLERIXAFOR | Mozobil | Multiple Myeloma or Non-Hodgkin's Lyjmphoma | AMD3100EU21 | NA | NCT00322842 | |
| PLERIXAFOR | Not marketed | Solid Tumors | MOZ15609-DFI12860 | MOZAIC | EudraCT: 2010-019340-40 | |
| PLERIXAFOR | Mozobil | Non-Hodgkin's Lymphoma | EFC12482 | NA | NCT01767714 | |
| PLERIXAFOR | Mozobil | Non-Hodgkin's Lymphoma | MOZ11809 | NA | NCT01164475 | |
| PRISTINAMYCIN | Pyostacin | Infection | PRIST_L_01683 | NA | NCT00393744 | |
| PROSTAGLANDINE E2 RECEPTOR ANGONIST | Not marketed | Open Angle Glaucoma or Ccular Hypertension | TDR13459 | NA | NCT02531152 |
References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted